Archives: Agenda

Clinical operations in rare disease trials have unique challenges due to small patient populations, limited understanding of the disease, and lack of established clinical endpoints. In this case study, we will explore:

• Adaptive trials designs to adjust clinical protocols based on interim results
• Specialized approaches to managing sponsor and site relationship
• Decentralized trials and leveraging technology to perform remote assessments
• Collaboration with patient communities and others

We may also discuss approaches that we previously employed but concluded as not suitable or too premature for rare disease trials.

• Find out when you can waive the need for Consent Forms
• When needed, ensure that Informed Consent Forms include key information
• Implement decentralized clinical trial elements to improve trial participant engagement, recruitment, enrollment, and retention

• Delving into the transformative impact of AI across the healthcare and life sciences ecosystem
• Exploring how AI technologies are revolutionizing drug discovery, enhancing clinical trial efficiency, and enabling more personalized patient care.
• Streamlining early-stage research and optimizing real-world applications in patient monitoring and therapeutic delivery
• How AI is paving the way for faster, more precise, and impactful healthcare solutions
• Insights into the latest AI-driven innovations and how these advancements are shaping the future of healthcare from concept to patient outcomes

• Begin with the end in mind: Termination Clause
• Identify and access file repositories
• Understand PII and security requirements
• Close out projects in the storage phase
• Secure vendor-backed documents and files
• Reconcile finances and finalize invoices
• Issue termination letters
• Complete contract close-out

• Aligning the clinical trial ecosystem to be operationally efficient and reduce delays in supply deliverables
• Fine-tuning the clinical supply vendor partnership: How can sponsors and service providers start using guidance in totality instead of in silos?
• Maintaining open communication with manufacturers to address precise trial needs and perfect demand planning
• Working in tandem across the trial ecosystem to better manage demands for increasingly complex clinical supply needs

• Aligning vendor expertise with study needs
• Assessing operational transparency and communication
• Balancing innovation with compliance

• Showcasing and defending the clinical operations strategy and outcome for pivotal studies during Sponsor regulatory inspections as the culmination of years of intense and important work; or the “Super Bowl” of Clinical Operations
• Sharing best practices based on real-life examples, for surviving and thriving during FDA and EMA Sponsor regulatory inspections from the Clinical Operations viewpoint
• Collaborating with QA and other cross-functional partners for success
• Best practices in logistics and Clin Ops teamwork in advance of, during and after the inspections
• Common, recent findings related to Clinical Operations during inspections

• Uncover and understand stakeholder and vendor business requirements
  • Who’s bringing what to the party?
  • Quality/Speed/Price
• Various development phases and vendor types
  • Business risks
  • Legal considerations
  • Vendor types
    • Early research/ development
    • CROs
    • Clinical sites and collaborations/HCPs
    • CMO/CDMOs
• Escalations and governance as a safety net